Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spon...

por Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, Xenofon
Publicado 2020